Llwytho...
BCL-2 inhibition in AML: an unexpected bonus?
B-cell lymphoma 2 (BCL-2) was discovered at the breakpoint of the t(14;18) in follicular lymphoma >30 years ago. Although inhibition of BCL-2 first proved valuable in lymphoid malignancies, clinical progress in myeloid malignancies lagged. Here, we summarize the basic biology and preclinical resu...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Blood |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
American Society of Hematology
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6235069/ https://ncbi.nlm.nih.gov/pubmed/30037885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-03-828269 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|